Dr. Jack Regan, CEO and Founder of LexaGene gives an update to BioPub Investment group on January 26, 2021.
The global bioburden testing market for bio-pharma contamination is approximately $10B, with over 350M tests run annually. LexaGene provides early detection for mycoplasma, aiding in validating product quality for biopharmaceutical manufacturers.
Single-use manufacturing has provided for a large degree of flexibility in terms of production volumes but have also brought about efficiencies in sterility control by reducing hands on cleaning and sterilization necessary for stainless steel.
On-site qPCR testing lets veterinarians make better treatment decisions faster than waiting on culture and sensitivity testing from a reference laboratory.
Veterinary Antimicrobial Stewardship programs are critical to not only improve patient outcomes, but support global action against antimicrobial resistance.